James Seibold
Scleroderma Research Consultants LLC · Scleroderma Research Consultants LLC, Avon, CT, · Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James Seibold as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00848107 · Open-Label Study of Oral Treprostinil in Digital UlcersUnited Therapeutics · terminated · Systemic Sclerosis · principal investigator
- Ph2NCT00775463 · Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineUnited Therapeutics · completed · Systemic Sclerosis, Scleroderma · principal investigator
- Ph3NCT00077584 · Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaActelion · completed · Digital Ulcers, Systemic Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:50 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- Cyclophosphamide versus placebo in scleroderma lung disease.N Engl J Med · 20061,237 citationsRCR 34.8
- Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.Arthritis Rheum · 2004509 citationsRCR 14.8
- Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.N Engl J Med · 2018451 citationsRCR 19.5
- Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.Arthritis Rheum · 2007371 citationsRCR 9.0
- Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Ann Rheum Dis · 2011358 citationsRCR 12.4
- Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Am J Respir Crit Care Med · 2007320 citationsRCR 9.7
- Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.Ann Intern Med · 1994300 citationsRCR 12.0
- Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.Clin Pharmacol Ther · 1999264 citationsRCR 8.9
- A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.Arthritis Rheum · 2001257 citationsRCR 7.5
- The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.J Rheumatol · 1998229 citationsRCR 6.5